Literature DB >> 33414788

A Novel Gene Delivery Vector of Agonistic Anti-Radioprotective 105 Expressed on Cell Membranes Shows Adjuvant Effect for DNA Immunization Against Influenza.

Tatsuya Yamazaki1, Mrityunjoy Biswas1, Kouyu Kosugi2, Maria Nagashima2, Masanori Inui1, Susumu Tomono1, Hidekazu Takagi1, Isao Ichimonji1, Fumiaki Nagaoka1, Akira Ainai3, Hideki Hasegawa3, Joe Chiba2, Sachiko Akashi-Takamura1.   

Abstract

Radioprotective 105 (RP105) (also termed CD180) is an orphan and unconventional Toll-like receptor (TLR) that lacks an intracellular signaling domain. The agonistic anti-RP105 monoclonal antibody (mAb) can cross-link RP105 on B cells, resulting in the proliferation and activation of B cells. Anti-RP105 mAb also has a potent adjuvant effect, providing higher levels of antigen-specific antibodies compared to alum. However, adjuvanticity is required for the covalent link between anti-RP105 mAb and the antigen. This is a possible obstacle to immunization due to the link between anti-RP105 mAb and some antigens, especially multi-transmembrane proteins. We have previously succeeded in inducing rapid and potent recombinant mAbs in mice using antibody gene-based delivery. To simplify the covalent link between anti-RP105 mAb and antigens, we generated genetic constructs of recombinant anti-RP105 mAb (αRP105) bound to the transmembrane domain of the IgG-B cell receptor (TM) (αRP105-TM), which could enable the anti-RP105 mAb to link the antigen via the cell membrane. We confirmed the expression of αRP105-TM and the antigen hemagglutinin, which is a membrane protein of the influenza virus, on the same cell. We also found that αRP105-TM could activate splenic B cells, including both mature and immature cells, depending on the cell surface RP105 in vitro. To evaluate the adjuvanticity of αRP105-TM, we conducted DNA immunization in mice with the plasmids encoding αRP105-TM and hemagglutinin, followed by challenge with an infection of a lethal dose of an influenza virus. We then obtained partially but significantly hemagglutinin-specific antibodies and observed protective effects against a lethal dose of influenza virus infection. The current αRP105-TM might provide adjuvanticity for a vaccine via a simple preparation of the expression plasmids encoding αRP105-TM and of that encoding the target antigen.
Copyright © 2020 Yamazaki, Biswas, Kosugi, Nagashima, Inui, Tomono, Takagi, Ichimonji, Nagaoka, Ainai, Hasegawa, Chiba and Akashi-Takamura.

Entities:  

Keywords:  DNA immunization; RP105; adjuvant; agonistic antibody; antibody gene-vector delivery; cell membrane; influenza; targeting antigen to B cells

Mesh:

Substances:

Year:  2020        PMID: 33414788      PMCID: PMC7783388          DOI: 10.3389/fimmu.2020.606518

Source DB:  PubMed          Journal:  Front Immunol        ISSN: 1664-3224            Impact factor:   7.561


  69 in total

Review 1.  The interleukin-1 receptor/Toll-like receptor superfamily: signal transduction during inflammation and host defense.

Authors:  L A O'Neill
Journal:  Sci STKE       Date:  2000-08-08

Review 2.  B cells: from early development to regulating allergic diseases.

Authors:  Konstantinos Samitas; Jan Lötvall; Apostolos Bossios
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2010-05-11       Impact factor: 4.291

3.  Hydrodynamics-based procedure involves transient hyperpermeability in the hepatic cellular membrane: implication of a nonspecific process in efficient intracellular gene delivery.

Authors:  Naoki Kobayashi; Makiya Nishikawa; Kazuhiro Hirata; Yoshinobu Takakura
Journal:  J Gene Med       Date:  2004-05       Impact factor: 4.565

4.  Rituximab infusion promotes rapid complement depletion and acute CD20 loss in chronic lymphocytic leukemia.

Authors:  Adam D Kennedy; Paul V Beum; Michael D Solga; David J DiLillo; Margaret A Lindorfer; Charles E Hess; John J Densmore; Michael E Williams; Ronald P Taylor
Journal:  J Immunol       Date:  2004-03-01       Impact factor: 5.422

5.  S1P1 receptor directs the release of immature B cells from bone marrow into blood.

Authors:  Maria L Allende; Galina Tuymetova; Bridgin G Lee; Eliana Bonifacino; Yun-Ping Wu; Richard L Proia
Journal:  J Exp Med       Date:  2010-04-19       Impact factor: 14.307

6.  Cross-protection against a lethal influenza virus infection by DNA vaccine to neuraminidase.

Authors:  Z Chen; S Kadowaki; Y Hagiwara; T Yoshikawa; K Matsuo; T Kurata; S Tamura
Journal:  Vaccine       Date:  2000-08-01       Impact factor: 3.641

7.  Targeting antigens to CD180 rapidly induces antigen-specific IgG, affinity maturation, and immunological memory.

Authors:  Jay W Chaplin; Craig P Chappell; Edward A Clark
Journal:  J Exp Med       Date:  2013-09-09       Impact factor: 14.307

Review 8.  Cancer DNA vaccines: current preclinical and clinical developments and future perspectives.

Authors:  Alessandra Lopes; Gaëlle Vandermeulen; Véronique Préat
Journal:  J Exp Clin Cancer Res       Date:  2019-04-05

Review 9.  Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4.

Authors:  Shuang Qin; Linping Xu; Ming Yi; Shengnan Yu; Kongming Wu; Suxia Luo
Journal:  Mol Cancer       Date:  2019-11-06       Impact factor: 27.401

Review 10.  Transitional B cells involved in autoimmunity and their impact on neuroimmunological diseases.

Authors:  Yang Zhou; Ying Zhang; Jinming Han; Mengge Yang; Jie Zhu; Tao Jin
Journal:  J Transl Med       Date:  2020-03-17       Impact factor: 5.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.